Amado Veronica Moreira, Fernandes Caio Júlio César Dos Santos, Salibe-Filho William, Gazzana Marcelo Basso, Rocha Ana Thereza, Yoo Hugo Hyung Bok, Bernardo Wanderley Marques, Tanni Suzana
. Universidade de Brasília - UnB - Brasília (DF) Brasil.
. Grupo de Circulação Pulmonar, Departamento de Cardiopneumologia, Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil.
J Bras Pneumol. 2025 Jun 13;51(2):e20240314. doi: 10.36416/1806-3756/e20240314. eCollection 2025.
Venous thromboembolism (VTE) is the third most common acute cardiovascular syndrome after acute myocardial infarction and stroke. In recent years, there has been an increase in the incidence of VTE, related to population aging and common comorbidities in the elderly, including chronic cardiorespiratory disease and cancer. On the other hand, disease-related mortality, particularly for pulmonary embolism (PE), shows a decreasing trend, which can be explained by improvements in diagnostic imaging, advances in available therapies, and greater adherence to patient management protocols. The guidelines presented here provide recommendations for the pharmacological treatment of PE in Brazil, on the basis of scientific evidence and with a focus on common practical issues. Six Patient, Intervention, Comparison, and Outcome questions were developed by a group of experts on the topic. Systematic reviews of randomized clinical trials were conducted for each question, with meta-analyses being performed when possible. The level of evidence and strength of recommendation were defined in accordance with the Grading of Recommendations Assessment, Development, and Evaluation approach. With these guidelines, we expect to provide relevant, up-to-date information on the pharmacological treatment of PE.
静脉血栓栓塞症(VTE)是仅次于急性心肌梗死和中风的第三大常见急性心血管综合征。近年来,VTE的发病率有所上升,这与人口老龄化以及老年人常见的合并症有关,包括慢性心肺疾病和癌症。另一方面,疾病相关的死亡率,尤其是肺栓塞(PE)的死亡率呈下降趋势,这可以通过诊断成像的改善、现有治疗方法的进步以及对患者管理方案的更严格遵守来解释。此处呈现的指南基于科学证据并聚焦于常见实际问题,为巴西PE的药物治疗提供建议。一组该主题的专家提出了六个患者、干预措施、对照和结局问题。针对每个问题进行了随机临床试验的系统评价,并在可能的情况下进行荟萃分析。证据水平和推荐强度根据推荐评估、制定和评价分级方法来定义。通过这些指南,我们期望提供有关PE药物治疗的相关、最新信息。